MemonMGulRGulA, et al. Esketamine for treatment-resistant depression in Pakistan: a promising strategy. Hosp Pharm. Published online 2025. doi:10.1177/00185787251384516
2.
HamiltonSP.The promise of psychiatric pharmacogenomics. Biol Psychiatry. 2015;77(1):29-35. doi:10.1016/j.biopsych.2014.09.009
3.
van SchaikRHNMüllerDJSerrettiAIngelman-SundbergM.Pharmacogenetics in psychiatry: an update on clinical usability. Front Pharmacol. 2020;11:575540. doi:10.3389/fphar.2020.575540
4.
KaramperisKKorominaMPapantoniouP, et al. Economic evaluation in psychiatric pharmacogenomics: a systematic review. Pharmacogenomics J. 2021;21(4):533-541. doi:10.1038/s41397-021-00249-1
5.
HiemkeCBergemannNClementHW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1-2):9-62. doi:10.1055/s-0043-116492
6.
KoopmansABBraakmanMHVinkersDJHoekHWvan HartenPN.Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19. Transl Psychiatry. 2021;11(1):141. doi:10.1038/s41398-020-01129-1
7.
CPIC. Clinical Pharmacogenetics implementation Consortium (CPIC website). Available at: https://cpicpgx.org/guidelines/ (accessed October 25, 2025).
8.
AdiukwuFAdesokunOEssienE, et al. Pharmacogenetic testing in psychiatry: perspective on clinical utility. Asian J Psychiatr. 2023;86:103674. doi:10.1016/j.ajp.2023.103674
9.
AlchakeeAAhmedMEldohajiLAlhajHSaber-AyadM.Pharmacogenomics in psychiatry practice: the value and the challenges. Int J Mol Sci. 2022;23(21):13485. doi:10.3390/ijms232113485
10.
BelančićAPavešić RadonjaAGanociLVitezićDBožinaN.Challenging pharmacotherapy management of a psychotic disorder due to a delicate pharmacogenetic profile and drug-drug interactions: a case report and literature review. Croat Med J. 2024;65(4):383-395. doi:10.3325/cmj.2024.65.383
